Show source-provided references
2. La historia olvidada del alzhéimer: Recordando a Oskar Fischer
3. The Lancet Commission on Dementia Prevention, Intervention, and Care: A call for action
10.1017/ipm.2018.4 ↗6. Teleanu, D.M., Niculescu, A.G., Lungu, I.I., Radu, C.I., Vladâcenco, O., Roza, E., Costăchescu, B., Grumezescu, A.M., and Teleanu, R.I. (2022). An Overview of Oxidative Stress, Neuroinflammation, and Neurodegenerative Diseases. Int. J. Mol. Sci., 23.
10.3390/ijms23115938 ↗9. Bello-Corral, L., Seco-Calvo, J., Molina Fresno, A., González, A.I., Llorente, A., Fernández-Lázaro, D., and Sánchez-Valdeón, L. (2024). Prevalence of ApoE Alleles in a Spanish Population of Patients with a Clinical Diagnosis of Alzheimer’s Disease: An Observational Case-Control Study. Medicina, 60.
10.3390/medicina60121941 ↗10. Modifiable, Non-Modifiable, and Clinical Factors Associated with Progression of Alzheimer’s Disease
10.3233/JAD-201182 ↗13. The role of nutrition in Alzheimer’s disease
16. Soluble and insoluble protein aggregates, endoplasmic reticulum stress, and vascular dysfunction in Alzheimer’s disease and cardiovascular diseases
10.1007/s11357-023-00748-y ↗19. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences
10.3758/BF03193146 ↗20. Sample size, power and effect size revisited: Simplified and practical approaches in pre-clinical, clinical and laboratory studies
10.11613/BM.2021.010502 ↗21. (2013). World Medical Association World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA, 310, 2191–2194.
10.1001/jama.2013.281053 ↗22. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
10.1016/j.jalz.2011.03.004 ↗23. International Classification of Diseases—11th revision: From design to implementation
25. José, M., Fructuoso, P., García Revilla, R., Moure, O.M., and Moure, R.C. (2025). Analysis of Aging in Spain: Contemporary Sociological and Demographic Implications. Societies, 15.
10.3390/soc15020046 ↗26. Riedel, B.C., Thompson, P.M., and Brinton, R.D. (2016). Age, APOE and Sex: Triad of Risk of Alzheimer’s Disease. J. Steroid Biochem. Mol. Biol., 160.
10.1016/j.jsbmb.2016.03.012 ↗27. Aging and Alzheimer’s disease: Comparison and associations from molecular to system level
10.1111/acel.12802 ↗28. Azam, S., Haque, M.E., Balakrishnan, R., Kim, I.S., and Choi, D.K. (2021). The Ageing Brain: Molecular and Cellular Basis of Neurodegeneration. Front. Cell Dev. Biol., 9.
10.3389/fcell.2021.683459 ↗29. Fernández-Lázaro, D., Garrosa, E., Seco-Calvo, J., and Garrosa, M. (2022). Potential Satellite Cell-Linked Biomarkers in Aging Skeletal Muscle Tissue: Proteomics and Proteogenomics to Monitor Sarcopenia. Proteomes, 10.
10.3390/proteomes10030029 ↗30. Alzheimer’s disease as a women’s health challenge: A call for action on integrative precision medicine approaches
10.1038/s44294-024-00021-3 ↗31. Di Sex difference in biological change and mechanism of Alzheimer’s disease: From macro- to micro-landscape
10.1016/j.arr.2023.101918 ↗34. Calvo, N., and Einstein, G. (2023). Steroid hormones: Risk and resilience in women’s Alzheimer disease. Front. Aging Neurosci., 15.
10.3389/fnagi.2023.1159435 ↗35. Sex differences in brain aging among adults with family history of Alzheimer’s disease and APOE4 genetic risk
10.1016/j.nicl.2021.102620 ↗37. Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer’s disease: Findings from three well-characterized cohorts
10.1016/j.jalz.2018.04.010 ↗38. The effect of the age at school entry on educational attainment and field of study: An analysis using the Spanish census
10.1007/s10734-023-01053-5 ↗39. Education reduces cognitive dysfunction in Alzheimer’s disease by changing regional cerebral perfusion: An in-vivo arterial spin labeling study
10.1007/s10072-023-06696-x ↗40. Educational attainment, structural brain reserve and Alzheimer’s disease: A Mendelian randomization analysis
10.1093/brain/awac392 ↗41. Modifiable pathways in Alzheimer’s disease: Mendelian randomisation analysis
10.1136/bmj.j5375 ↗42. Cognitive performance protects against Alzheimer’s disease independently of educational attainment and intelligence
10.1038/s41380-022-01695-4 ↗43. Summative Effects of Vascular Risk Factors on the Progression of Alzheimer Disease
10.1111/jgs.16181 ↗44. Age, Vascular Health, and Alzheimer’s disease Biomarkers in an Elderly Sample
10.1002/ana.25071 ↗45. Hypertension induces brain β-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature
10.1161/HYPERTENSIONAHA.112.195511 ↗47. Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study
10.1093/brain/awac354 ↗48. Meta-analysis of modifiable risk factors for Alzheimer’s disease
50. Efectos del tratamiento y las drogas anti-hipertensivas sobre la función cognitiva: Deterioro cognitivo, demencia y enfermedad de Alzheimer
52. Hypertension and longitudinal changes in cerebral blood flow: The SMART-MR study
10.1002/ana.23554 ↗53. Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimer’s (HEART) Trial
10.3233/JAD-161198 ↗54. Testa, G., Giannelli, S., Staurenghi, E., Cecci, R., Floro, L., Gamba, P., Sottero, B., and Leonarduzzi, G. (2024). The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer’s Disease: A Possible Target for the Disease Treatment. Int. J. Mol. Sci., 25.
10.3390/ijms252413637 ↗55. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study
10.1161/01.ATV.20.10.2255 ↗56. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer’s disease
10.1159/000026149 ↗57. Association of Hypercholesterolemia with Alzheimer’s Disease Pathology and Cerebral Amyloid Angiopathy
10.3233/JAD-191023 ↗58. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease
10.7326/0003-4819-137-3-200208060-00006 ↗60. Hypercholesterolemia and Alzheimer’s Disease: Unraveling the Connection and Assessing the Efficacy of Lipid-Lowering Therapies
10.3233/JAD-240388 ↗61. O’Connell, E.M., and Lohoff, F.W. (2020). Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders. Front. Neurosci., 14.
10.3389/fnins.2020.00609 ↗63. Al-Kuraishy, H.M., Sulaiman, G.M., Mohammed, H.A., Mohammed, S.G., Al-Gareeb, A.I., Albuhadily, A.K., Dawood, R.A., Al Ali, A., and Abu-Alghayth, M.H. (2025). Amyloid-β and heart failure in Alzheimer’s disease: The new vistas. Front. Med., 12.
10.3389/fmed.2025.1494101 ↗64. Arega, Y., and Shao, Y. (2022). Heart failure and late-onset Alzheimer’s disease: A Mendelian randomization study. Front. Genet., 13.
10.3389/fgene.2022.1015674 ↗65. Left Ventricular Ejection Fraction and Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Pathology in Cognitively Normal Older Adults: The CABLE Study
10.3233/JAD-201222 ↗66. Murphy, J., Le, T.N.V., Fedorova, J., Yang, Y., Krause-Hauch, M., Davitt, K., Zoungrana, L.I., Fatmi, M.K., Lesnefsky, E.J., and Li, J. (2022). The Cardiac Dysfunction Caused by Metabolic Alterations in Alzheimer’s Disease. Front. Cardiovasc. Med., 9.
10.3389/fcvm.2022.850538 ↗67. Associations between coronary heart disease and risk of cognitive impairment: A meta-analysis
10.1002/brb3.2108 ↗68. Cerebral amyloid-β deposition in patients with heart disease or carotid occlusive disease: A systematic review and meta-analysis
10.1016/j.jns.2023.120551 ↗69. Atrial Fibrillation Is Associated with Cognitive Impairment, All-Cause Dementia, Vascular Dementia, and Alzheimer’s Disease: A Systematic Review and Meta-Analysis
10.1007/s11606-021-06954-8 ↗71. Vascular pathology and pathogenesis of cognitive impairment and dementia in older adults
76. Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2
10.1016/j.jns.2009.09.022 ↗77. Singh, D.D., Shati, A.A., Alfaifi, M.Y., Elbehairi, S.E.I., Han, I., Choi, E.-H., Yadav, D.K., Singh, D.D., Shati, A.A., and Alfaifi, M.Y. (2022). Development of Dementia in Type 2 Diabetes Patients: Mechanisms of Insulin Resistance and Antidiabetic Drug Development. Cells, 11.
10.3390/cells11233767 ↗78. Kong, Y., Wang, F., Wang, J., Liu, C., Zhou, Y., Xu, Z., Zhang, C., Sun, B., and Guan, Y. (2020). Pathological Mechanisms Linking Diabetes Mellitus and Alzheimer’s Disease: The Receptor for Advanced Glycation End Products (RAGE). Front. Aging Neurosci., 12.
10.3389/fnagi.2020.00217 ↗79. Kciuk, M., Kruczkowska, W., Gałęziewska, J., Wanke, K., Kałuzińska-Kołat, Ż., Aleksandrowicz, M., and Kontek, R. (2024). Alzheimer’s Disease as Type 3 Diabetes: Understanding the Link and Implications. Int. J. Mol. Sci., 25.
10.3390/ijms252211955 ↗